University of Maryland GCCC
Welcome,         Profile    Billing    Logout  
 1 Trial 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
D'Adamo, Chris
NCT04981275: A Multi-omic Approach to Evaluate and Characterize the Polycystic Ovary Syndrome (PCOS) Phenotype

Completed
N/A
81
US
No intervention study
Onegevity Health, University of Maryland, Baltimore
Polycystic Ovary Syndrome
01/22
09/23
NCT05499858: Evaluating Effectiveness of Spices and Herbs to Increase Vegetable Intake Among Military

Recruiting
N/A
400
US
Spiced, Plain
Uniformed Services University of the Health Sciences, University of Maryland, Baltimore, Nova Institute for Health, Henry M. Jackson Foundation for the Advancement of Military Medicine, Pennington Biomedical Research Center, McCormick Science Institute
Dietary Intake
07/24
12/24
NCT06363721: A Pilot Study of a Commercially-available Oil Rinse Product (PerioPull™) on Markers of Dental Health

Recruiting
N/A
18
US
PerioPull™
Designs for Health
Oral Health
12/24
12/24
NCT06747624: A Crossover Clinical Trial Investigating the Effects of Geranylgeraniol (GG) Supplementation on Testosterone Levels in Healthy Men and Women Over an 18-week Period

Not yet recruiting
N/A
40
US
Geranylgeraniol 300 mg, Placebo
Designs for Health
Wellness, Health
09/25
10/25
Kaiser, Adeel
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
HAMMER, NCT05657873: A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
2
68
US
L-SABR, Liver Stereotactic Ablative Radiation Therapy, Anti-PD-(L)1 based immunotherapy, Standard of Care, Platinum based chemotherapy
Memorial Sloan Kettering Cancer Center
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, NSCLC, NSCLC Stage IV
12/25
12/25
SAMURAI, NCT05327686: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, Study

Recruiting
2
240
US
Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Axitinib, AG-013736, AG013736, Inlyta, Cabozantinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Stereotactic Ablative Radiotherapy, SABER, SABR, SBRT, Stereotactic Ablative Radiation Therapy
NRG Oncology, National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
06/28
06/32
Siddiqui, Mohummad M
NCT04698564: Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

Recruiting
2
20
US
Hyperpolarized 13C-Pyruvate
University of Maryland, Baltimore
Prostate Cancer
12/25
12/27

Download Options